Previous Article | Next Article 
Journal of Clinical Microbiology, May 2001, p. 1850-1854, Vol. 39, No. 5
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.5.1850-1854.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Prevalence of Human Immunodeficiency Virus Type 1 (HIV-1) Non-B
Subtypes in Foreigners Living in Madrid, Spain, and Comparison of the
Performances of the AMPLICOR HIV-1 MONITOR Version 1.0 and the New
Automated Version 1.5
Africa
Holguín,1
Belén
Aracil,2
Amparo
Álvarez,1
Carlos
Barros,2 and
Vincent
Soriano1,*
Service of Infectious Diseases, Hospital
Carlos III, Instituto de Salud Carlos III,1 and
Service of Microbiology and HIV Unit, Hospital de
Móstoles,2 Madrid, Spain
Received 10 July 2000/Returned for modification 16 October
2000/Accepted 21 February 2001
 |
ABSTRACT |
Plasma specimens collected in 1999 from 32 human immunodeficiency
virus type 1 (HIV-1)-infected foreigners living in Madrid, Spain, were
examined for the presence of non-B subtypes. Furthermore, plasma
viremia was quantified using two different AMPLICOR HIV-1 MONITOR
tests, version 1.0 and the new upgraded and automated version 1.5 (COBAS). Most patients came from Africa, where they most likely had
acquired HIV-1 infection through sexual contact. HIV-1 genetic
subtyping was based on the phylogenetic analysis of the
protease gene. Twenty-two subtype B, six subtype G, two subtype C, one subtype A, and one D subtype infection were found. Overall, non-B subtypes represented 31.25% of the study population. Irrespective of the HIV-1 variant, viral load values above the detection limit (200 HIV RNA copies/ml) increased from 56.2 to 71.9%
for results obtained using MONITOR version 1.0 and COBAS, respectively.
Moreover, significant differences in viral load values (>0.5 logs)
were recognized in up to 37.5% of samples. In summary, COBAS seemed to
be more reliable for testing plasma viral load in HIV-infected
immigrants living in Spain, one third of whom carried non-B subtypes.
 |
INTRODUCTION |
Human immunodeficiency virus type 1 (HIV-1) mutates rapidly, contributing to its high degree of genetic
heterogeneity in vivo (3). Methods based on nucleotide
sequence analyses allow the recognition of phylogenetic relationships
between different sequences. So far HIV-1 can be divided into three
distinct and highly divergent groups: M (major), O (outlier), and N
(new) (19, 25, 30). At least fourteen major genetic
variants can be recognized within HIV-1 group M, including several
subtypes (A, B, C, D, F, G, H, J, and K) and four major circulating
recombinant forms (CRF01-AE, CRF02-AG, CRF03-AB, and CRF04-cpx,
"complex") (19, 33). Classification of HIV-1 into
subtypes is based primarily on the analysis of genetic sequences coding
for the envelope (env) and other structural (gag, pol) proteins.
In Spain, as in North America and other Western European countries,
HIV-1 subtype B is the most prevalent HIV-1 variant (15). Non-B subtypes have been reported mainly in Africa, where a large diversity of HIV-1 variants has been found (18). However,
the prevalence of HIV-1 non-B subtypes seems to be increasing in North America (24, 34) and Europe (6, 10, 15, 16,
24), and limitations of the current commercial HIV-1
quantitation assays examining these specimens have been pointed out
recently (1, 2, 17, 32), since these tests were originally
designed on the basis of HIV-1 subtype B sequences. Herein we
investigate the prevalence of HIV-1 subtypes in a group of 32 infected
foreigners living in Madrid, Spain, and analyze the performance of two
different versions of the AMPLICOR HIV-1 MONITOR test in samples
belonging to these subjects.
 |
MATERIALS AND METHODS |
Blood specimens from 32 HIV-1-infected immigrants attending one
HIV unit located in Madrid were collected in 1999. Twenty-seven (84.4%) were from Africa, four (12.5%) were from South America, and
one (3.1%) was from Eastern Europe. Epidemiological and clinical data
are summarized in Table 1. Plasma
aliquots were separated from blood cells within 4 h following
phlebotomy and were frozen at
80°C until the time of analysis. The
CD4+ lymphocyte count was analyzed by flow cytometry
(Coulter, Barcelona, Spain).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Epidemiological features of the study population and
genetic heterogeneity in amino acid positions of the
protease gene product associated with resistance
|
|
The characterization of HIV-1 subtypes was performed by phylogenetic
analysis of the protease gene as previously described (16). We used 21 HIV-1 reference sequences belonging to
HIV-1 groups M and N having full-length genomes available at GenBank. The tree topology was obtained using the neighbor-joining program (27). Alignment of DNA sequences was performed using the
CLUSTAL W method (31). Pairwise distance matrices were
estimated using the Kimura two-parameter model with the DNADIST
program, as implemented in the PHYLIP software package
(13). Bootstrap resampling (1,000 data sets) of the
multiple alignment was done to test the statistical robustness of the tree.
Plasma viremia was quantified using the two different versions of the
AMPLICOR HIV-1 MONITOR test (Roche Diagnostics, Barcelona, Spain), a
reverse transcription-PCR-based assay designed for quantifying HIV-1
RNA in plasma (22). Version 1.0 was the original
commercial test. The other one was a prototype automated procedure of
version 1.5 (COBAS), in which HIV-1 RNA amplification and detection
take place on the COBAS AMPLICOR instrument (9). Both
methods differ in the primers used for reverse transcription and PCR,
the composition of the reverse transcription-PCR mixture, the thermal
cycling parameters, and the internal quantification standard RNA
(21, 32). Hypothetically, COBAS provides more reliable
viral load data, since it is substantially less influenced by viral
subtype (21).
Nucleotide sequence accession numbers.
Protease
sequences have been submitted to the GenBank database with the
accession numbers AF247007 to AF247038.
 |
RESULTS |
HIV-1 genetic subtype characterization and main epidemiological
features.
The presence of HIV-1 non-B subtypes in Spain has been
reported previously (15, 16). All patients enrolled in
this study were HIV-1-infected foreigners living in Madrid, mostly
coming from African countries (84.4%) where most HIV-1 subtypes
cocirculate (18). Interestingly, although all 32 subjects
had probably acquired HIV-1 infection in their country of origin, in
78% of the cases their first diagnosis was in Spain.
The epidemiological features of the study population and the assignment
of its genetic HIV-1 subtype are summarized in Table
1. Twenty-two
subtype B, six subtype G, two subtype C, one subtype
A, and one D
subtype infection were found. Phylogenetic tree topology
was supported
by high bootstrap values (Fig.
1).
Although sample
no. M1296 could not be assigned initially to a specific
known
subtype, when the tree was performed exclusively with this sample
and the reference strains, this specimen clustered within subtype
D
variants (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Phylogenetic tree of the HIV-1 protease
coding region from 32 foreigners living in Spain (bold). Bootstrap
resampling values (1,000 sets) are indicated. The lengths of the
branches are proportional to the relative evolutionary distances.
|
|
Overall, nearly one third (31.25%) of the HIV-1-infected foreigners
living in Madrid carried HIV-1 non-B subtypes. All of
them were
African. All but one were women, and seven of them admitted
to being
engaged in prostitution. The origins of individuals harboring
HIV-1
subtype G were Equatorial Guinea (
n = 3), Zaire
(
n = 1),
Cape Verde (
n = 1), and
Cameroon (
n = 1). All subjects carrying
subtypes A, C,
and D came from Equatorial Guinea, a former Spanish
colony.
Drug resistance mutations in non-B subtypes.
Genetic changes
associated with resistance to protease inhibitors were recognized in
both naive and pretreated individuals carrying HIV-1 non-B subtypes
(Table 1). For example, the secondary substitution Met36
Ile was
found in all seven naive subjects infected with non-B subtypes, while
the change Val77
Ile was seen in two subtype G specimens. These
changes have been associated with resistance to nelfinavir and
ritonavir, respectively (29). On the other hand, drug
resistance mutations in subjects with non-B subtypes under
antiretroviral therapy appeared at the same positions as those that
were reported for subtype B (29) (Table 1).
Performance of viral load tests.
Regardless of the HIV-1
variant, positive quantitative values above the detection limit (200 HIV-RNA copies/ml) increased from 56.2% for MONITOR version 1.0 to
71.9% for COBAS (Student's t test, P < 0.05) (Table 2). On average, the
newer method outperformed version 1.0 in all aspects of HIV-1 testing.
The differences between the geometric mean titers of version 1.0 (341,401) and COBAS (539,009) were found to be statistically
significant (Fisher exact test, P = 0.05).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Differences between HIV-1 plasma viral load results
provided by AMPLICOR HIV-1 MONITOR version 1.0 and COBAS
|
|
Differences in viral load values above 0.5 logs were considered
significant and were recognized in up to 37.5% of cases. They
occurred
more frequently in non-B rather than subtype B specimens
(60 versus
27.3%) (Table
2). One specimen belonging to subtype
G (M916) yielded
repeated discrepancies in plasma viremia above
2.5 logs. However, viral
load values were significantly higher
using version 1.0 in 4 of 10 HIV-1 non-B subtype specimens (Table
2). With respect to subtype B
specimens, 41% showed significantly
higher values using COBAS, and
18.2% showed higher values using
version 1.0.
 |
DISCUSSION |
Performance of two different versions of the AMPLICOR HIV-1
MONITOR test.
Quantitative values of plasma viremia using the
currently available viral load assays can be unreliable for testing
non-B subtypes or recombinant forms of HIV-1 (1, 5, 7, 11, 17). The AMPLICOR HIV-1 MONITOR test, version 1.0, was developed when little sequence information on HIV-1 subtypes was available (22). The primers used (SK431 and SK462) were designed on
the basis of a subtype B consensus sequence (22). This
fact explains the low performance of this assay for testing non-B
subtypes. It is estimated that HIV-1 subtypes A, E, F, and G were
underestimated by 10-fold or more. The use of COBAS, which was
developed to minimize subtype-related variation (21),
seemed to allow an equivalent quantitation of HIV-1 RNA regardless of
the subtype. It uses a set of primers (SK145 and SKCC1B) which are
based on a non-B subtype consensus sequence (21, 32). The
lower viremia values provided by COBAS in 40% of samples from subjects
carrying non-B subtypes and in 18.2% of those with subtype B found in
our study was an unexpected finding. It could be due to the difference
in how the amplicons are captured (microwells versus microbeads) by the
detection reagents used in the prototype automated test or the presence of mismatches in sample primer binding sites. The recognition of higher
levels of HIV-1 plasma viremia by either assay in two subjects carrying
subtypes G (M2773) and B (M1743) and being under triple or quadruple
antiretroviral combinations was also unexpected, but it might be
explained by noncompliance with the prescribed treatment noticed in
these subjects.
The high number of specimens showing significant differences (>0.5
log) in viral load values between the AMPLICOR quantification
versions
strongly reinforces the importance of always monitoring
HIV-1-infected
patients with the same version of any viral load
quantitation technique
(
17).
Epidemiological implications of the spreading of non-B
subtypes.
The presence of HIV-1 non-B subtypes in Spain has been
reported previously (15, 16). However, in our study nearly
one third of the population (31.25%) carried non-B subtypes. All 10 subjects infected with non-B subtypes came from Africa, where a large
variety of HIV-1 subtypes and recombinant forms are circulating (18). Seven of those 10 patients with HIV-1 non-B subtypes
were identified as prostitutes. The reported promiscuity of the three other individuals or their sexual partners should remain in question. Spreading of these minor HIV variants among native individuals in Spain
is of particular concern, as it seems to happen in other European
countries (10) and the United States (34).
The primary diagnosis of more than three-fourths of these patients
occurred in Spain. This reinforces the fact that HIV testing should be offered to all persons belonging to high-risk groups and/or emigrating from regions of high endemicity where testing is not available.
The spread of different HIV-1 subtypes in a single geographic region
coupled with intersubtype recombination (
16,
26)
has
serious implications for the efforts to control the AIDS pandemic.
The
impacts of the different genetic subtypes on pathogenesis,
the course
of HIV infection, transmissibility, vaccine efficacy,
and diagnosis
based on serologic (
20) or PCR assays (
2) are
not yet well known and must be further studied (
12). It
has
been previously reported that susceptibility to antiretroviral
drugs might differ between distinct subtypes (
8,
23). In
this study we have shown that mutations associated with resistance
to
protease inhibitors appear in HIV-1 non-B subtypes at the same
positions that they do in subtype B strains. This observation
suggests
that the distinct HIV-1 subtypes evolve convergently
at the genetic
level when antiretroviral drugs act as selective
forces
(
28).
Studies designed to monitor the spread of HIV-1 subtypes should be
encouraged. In areas where non-B subtypes represent a significant
proportion of infections, viral load quantitation tests able to
appropriately recognize the different viral variants should be
implemented.
 |
ACKNOWLEDGMENTS |
This work was funded in part by grants from Instituto de Salud
Carlos III, Comunidad Autónoma de Madrid (CAM), and
Asociación Investigación y Educación en SIDA (AIES).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: C/ Nueva Zelanda
54, 4° B, 28035 Madrid, Spain. Phone: 34-91 4532500. Fax: 34-91 733 6614. E-mail: vsoriano{at}dragonet.es.
 |
REFERENCES |
| 1.
|
Alaeus, A.,
K. Lidman,
A. Sönnerborg, and J. Albert.
1997.
Subtype-specific problems with quantification of plasma HIV-1 RNA.
AIDS
11:859-865[CrossRef][Medline].
|
| 2.
|
Arnold, C.,
K. Barlow,
S. Kaye,
C. Loveday,
P. Balfe, and J. Clewley.
1995.
HIV type 1 sequence subtype G transmission from mother to infant: failure of variant sequence species to amplify in the Roche Amplicor test.
AIDS Res. Hum. Retrovir.
11:999-1001[Medline].
|
| 3.
|
Coffin, J.
1995.
HIV population dynamic in vivo: implications for genetic variation, pathogenesis, and therapy.
Science
267:483-489.
|
| 4.
|
Cornelissen, M.,
G. Kampinga,
F. Zorgdrager,
J. Goudsmit, and The UNAIDS Network for HIV Isolation and Characterization.
1996.
HIV-1 subtypes defined by env show high frequency of recombinant gag genes.
J. Virol.
70:8209-8212[Abstract].
|
| 5.
|
Coste, J.,
B. Montes,
J. Reynes,
M. Peeters,
C. Segarra,
J.-P. Vendrell,
E. Delaporte, and M. Segondy.
1996.
Comparative evaluation of three assays for the quantitation of HIV-1 RNA in plasma.
J. Med. Virol.
50:293-302[CrossRef][Medline].
|
| 6.
|
Couturier, E.,
F. Damon,
P. Roques,
H. Flevry,
F. Barin,
J. Brunet,
F. Brun-Vézinet,
F. Simon, and the AC II Laboratory Network.
2000.
HIV-1 diversity in France, 1996-1998.
AIDS
14:289-296[CrossRef][Medline].
|
| 7.
|
Debyser, Z.,
E. Van Wijngaerden,
K. Laethem,
K. Beuselinck,
M. Reynders,
E. De Clercq,
J. Desmyter, and A. Vandamme.
1998.
Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV-1 type 1 subtype G strain.
AIDS Res. Hum. Retrovir.
14:453-459[Medline].
|
| 8.
|
Descamps, D.,
C. Apetrei,
G. Collin,
F. Damond,
F. Simon, and F. Brun-Vézinet.
1998.
Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.
AIDS
12:1109-1111[Medline].
|
| 9.
|
Di Domenico, N.,
H. Link,
R. Knobel,
T. Caratsch,
W. Weschler,
Z. Loewy, and M. Rosentraus.
1996.
COBAS Amplicor: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR.
Clin. Chemother.
42:1915-1923.
|
| 10.
|
Dietrich, U.,
H. Ruppach,
S. Gehring,
H. Knechten,
M. Knickmann,
H. Jäger,
E. Wolf,
R. Husak,
C. Orfanos,
H. Brede,
H. Rübsamen-Waigmann, and H. Von Briesen.
1997.
Large proportion of non-B subtypes and presence of zidovudine resistance mutations among German seroconverters.
AIDS
11:1532-1533[Medline].
|
| 11.
|
Dunne, A., and S. Crowe.
1997.
Comparison of branched DNA and reverse transcriptase PCR for quantifying six different HIV-1 subtypes in plasma.
AIDS
11:126-127[Medline].
|
| 12.
|
Expert Group of the Joint United Nations Programme on HIV/AIDS.
1997.
Implications of HIV variability for transmission: science and politic issues.
AIDS
11:1-15[CrossRef][Medline].
|
| 13.
|
Felsenstein, J.
1992.
PHYLIP (Phylogeny Inference Package), version 3.5c.
Department of Genetics, University of Washington, Seattle, Wash.
|
| 14.
|
Gobbers, E.,
K. Fransen,
T. Oosterlaken,
W. Janssens,
L. Heyndrickx,
T. Ivens,
K. Vereecken,
P. van de Wiel, and G. van der Groen.
1997.
Reactivity and amplification system with regard to different HIV-1 subtypes.
J. Virol. Methods
66:293-301[CrossRef][Medline].
|
| 15.
|
Holguín, A.,
B. Rodés,
U. Dietrich, and V. Soriano.
1999.
Human immunodeficiency viruses type 1 subtypes circulating in Spain.
J. Med. Virol.
53:856-860.
|
| 16.
|
Holguín, A.,
B. Rodés, and V. Soriano.
2000.
Recombinant human immunodeficiency viruses type 1 circulating in Spain.
AIDS Res. Hum. Retrovir.
16:501-511.
|
| 17.
|
Holguín, A.,
C. de Mendoza, and V. Soriano.
1999.
Comparison of three commercial methods for quantification of plasma viraemia in clinical specimens belonging to HIV-1 non-B subtypes.
Eur. J. Clin. Microbiol. Infect. Dis.
18:256-259[CrossRef][Medline].
|
| 18.
|
Janssens, W.,
A. Buvé, and J. Nkengasong.
1997.
The puzzle of HIV-1 subtypes in Africa.
AIDS
11:705-712[CrossRef][Medline].
|
| 19.
|
Korber, B.,
C. Kuiken,
B. Foley,
B. Hanh,
F. McCutchan,
J. Mellors, and J. Sodroski.
1998.
Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences.
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.Mex.
|
| 20.
|
Loussert-Ajaka, I.,
T. Ly,
M. Chaix,
D. Ingrand,
S. Saragosti,
A. Courouce,
F. Brun-Vézinet, and F. Simon.
1994.
HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients.
Lancet
343:1393-1394[CrossRef][Medline].
|
| 21.
|
Michael, N.,
S. Herman,
S. Kwok,
K. Dreyer,
J. Wang,
C. Christopherson,
J. Spadoro,
K. Young,
V. Polonis,
F. McCutchan,
J. Carr,
J. Mascola,
L. Jagodzinski, and M. Robb.
1999.
Development of calibrated viral load standards for group M subtypes of HIV-1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes.
J. Clin. Microbiol.
37:2557-2563[Abstract/Free Full Text].
|
| 22.
|
Mulder, J.,
N. McKinney,
C. Christopherson,
J. Sninsky,
L. Greenfield, and S. Kwok.
1994.
Rapid and simple PCR assay for quantitation of HIV-1 RNA: application to acute retroviral infection.
J. Clin. Microbiol.
32:292-300[Abstract/Free Full Text].
|
| 23.
|
Palmer, S.,
A. Alaeus,
J. Albert, and S. Cox.
1998.
Drug susceptibility of subtypes A, B, C, D, and E HIV-1 primary isolates.
AIDS Res. Hum. Retrovir.
14:157-162[Medline].
|
| 24.
|
Paraskevis, D., and A. Hatzakis.
1999.
Molecular epidemiology of HIV-1 infection.
AIDS Reviews
1:238-249.
|
| 25.
|
Peeters, M.,
F. Liegeois,
N. Torimiro,
A. Bourgeois,
E. Mpoudi,
L. Vergne,
E. Saman,
E. Delaporte, and S. Saragosti.
1999.
Characterization of a highly replicative intergroup M/O HIV-1 recombinant isolated from a Cameroonian patient.
J. Virol.
73:7368-7375[Abstract/Free Full Text].
|
| 26.
|
Quiñones-Mateu, M., and E. Arts.
1999.
Recombination in HIV-1: update and implications.
AIDS Reviews
1:89-100.
|
| 27.
|
Saitou, N., and M. Nei.
1987.
The neighbor-joining method: a new method for reconstructing phylogenetic trees.
Mol. Biol. Evol.
4:406-425[Abstract].
|
| 28.
|
Sato, H.,
Y. Tomita,
K. Shibamura,
T. Shiino,
T. Miyakuni, and Y. Takebe.
2000.
Convergent evolution of RT genes of HIV-1 subtype E and B following nucleoside analogue RT inhibitor therapies.
J. Virol.
74:5357-5362[Abstract/Free Full Text].
|
| 29.
|
Schinazi, R.,
B. Larder, and J. Mellors.
1999.
Mutations in retroviral genes associated with drug resistance: 1999-2000 update.
Int. Antivir. News
7:46-69.
|
| 30.
|
Simon, F.,
P. Mauclère,
P. Roques,
I. Loussert-Ajaka,
M. Müller-Trutwin,
S. Saragosti,
M. Georges-Courbot,
F. Barré-Sinoussi, and F. Brun-Vézinet.
1998.
Identification of a new HIV-1 distinct from group M and group O.
Nat. Med.
4:1032-1037[CrossRef][Medline].
|
| 31.
|
Thompson, J.,
D. Higgins, and T. Gibson.
1994.
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res.
22:4673-4680[Abstract/Free Full Text].
|
| 32.
|
Triques, K.,
J. Coste,
J. Perret,
C. Segarra,
E. Mpoudi,
J. Reynes,
E. Delaporte,
A. Butcher,
K. Dreyer,
S. Herman,
J. Spadoro, and M. Peeters.
1999.
Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of HIV-1.
J. Clin. Microbiol.
37:110-116[Abstract/Free Full Text].
|
| 33.
|
Triques, K.,
A. Bourgeois,
N. Vidal,
E. Mpoudi-Ngole,
C. Mulanga-Kabeya,
N. Nzilambi,
N. Torimiro,
E. Saman,
E. Delaporte, and M. Peeters.
2000.
Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K.
AIDS Res. Hum. Retrovir.
16:139-151[CrossRef][Medline].
|
| 34.
|
Weidle, P.,
C. Ganea,
K. Irwin,
D. Pieniazek,
J. McGowan,
N. Olivo,
A. Ramos,
C. Schable,
R. Lal,
S. Holmberg, and J. Ernst.
2000.
Presence of HIV-1 group M, non-B subtypes in Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States.
J. Infect. Dis.
181:470-475[CrossRef][Medline].
|
Journal of Clinical Microbiology, May 2001, p. 1850-1854, Vol. 39, No. 5
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.5.1850-1854.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Holguin, A., Lopez, M., Molinero, M., Soriano, V.
(2008). Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. J. Clin. Microbiol.
46: 2918-2923
[Abstract]
[Full Text]
-
Foulongne, V., Montes, B., Didelot-Rousseau, M.-N., Segondy, M.
(2006). Comparison of the LCx Human Immunodeficiency Virus (HIV) RNA Quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan Assays for Quantitation of HIV Type 1 RNA in Plasma.. J. Clin. Microbiol.
44: 2963-2966
[Abstract]
[Full Text]
-
Tobin, N. H., Learn, G. H., Holte, S. E., Wang, Y., Melvin, A. J., McKernan, J. L., Pawluk, D. M., Mohan, K. M., Lewis, P. F., Mullins, J. I., Frenkel, L. M.
(2005). Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus. J. Virol.
79: 9625-9634
[Abstract]
[Full Text]
-
Brambilla, D. J., Jennings, C., Morack, R., Granger, S., Bremer, J. W.
(2004). Comparison of the Sensitivities of the Version 1.5 and Version 1.0 Ultrasensitive Roche AMPLICOR HIV-1 MONITOR Kits at Low Concentrations of Human Immunodeficiency Virus RNA. J. Clin. Microbiol.
42: 2819-2820
[Abstract]
[Full Text]
-
Holzl, G., Stocher, M., Leb, V., Stekel, H., Berg, J.
(2003). Entirely Automated Quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Plasma by Using the Ultrasensitive COBAS AMPLICOR HIV-1 Monitor Test and RNA Purification on the MagNA Pure LC Instrument. J. Clin. Microbiol.
41: 1248-1251
[Abstract]
[Full Text]
-
Martin, J C, Holguin, A, Soriano, V
(2002). Prevalence of different HIV-1 subtypes in an urban clinic in Madrid. Sex. Transm. Infect.
78
: e1-e1
[Abstract]
[Full Text]